Featured

Three investor relations (IR) searches came across our desk within roughly a week. Then more conversations followed. The last time I saw IR hiring pick up this quickly was around 2021 and early 2022, when capital was moving more actively through the life sciences market. Hiring ultimately slowed as market conditions tightened. Now, that activity…

We see it often: new financing changes the leadership a company needs, new data reshapes the clinical or development path, commercialization brings new operational demands into focus, a transaction or public-market expectation raises the bar for governance, communications, and execution. Boards and executive teams face the challenge of expanding or changing their leadership team to…

You’ve been searching for a critical leader for months. You’ve interviewed candidates. Some didn’t fit, and others dropped out. Maybe you have a strong finalist and things are on track. Or maybe, after three months, you’re still having the same conversations you had at the start. When a search stalls, more candidates aren’t always the…

How experienced directors and operators help build credibility in emerging biotech categories When Eli Lilly agreed to acquire AtaiBeckley for up to $2.8 billion, most of the coverage focused on the science and the price. Both matter. But the deal also signals something larger than a single transaction. It follows AbbVie’s move into the space…

In professional sports, there is a familiar pattern. The same coaches move from team to team. They have won before, built reputations, and proven they can lead under pressure. Mike McCarthy is a good example. He won a Super Bowl in Green Bay, had a very different run in Dallas, and now enters another chapter…

For nearly two years, much of the life sciences industry operated in survival mode. Capital was tight, financing windows were limited, and leadership teams focused on preserving runway. Hiring slowed dramatically, and many organizations learned to operate with extremely lean teams. However, the environment is beginning to shift. Capital markets have loosened. Companies are raising…

We’re already seeing it in early 2026: leadership decisions are starting earlier, and the cost of getting them wrong is harder to unwind. This isn’t about a single market moment. Capital is beginning to move again, though selectively. Boards are more engaged. Expectations around governance and execution are rising. At the same time, leadership teams…

We’re proud to present an exclusive Q&A with Lindsay Mateo, MBA, a visionary leader in the pharmaceutical and healthcare services sector. In this deep-dive interview, Lindsay shares her insights on navigating challenges in the healthcare industry, fostering a positive work culture, and the lessons learned from a career influenced by exemplary leadership. Explore how her experiences and strategies are driving change and innovation in an evolving landscape.

Explore our engaging discussion with Rob Carson, President, CEO, and Board Director of Ultivue, in this LifeSci Search Executive Insight. Rob reflects on his leadership journey, shaped by his father’s influence, his approaches to fostering a positive work environment, and his perspectives on the opportunities and challenges facing the spatial biology field. Gain valuable insights from Rob’s experienced viewpoint on leadership and industry innovation.